STOCK TITAN

LEMAITRE VASCULAR (LMAT) SEC Filings, Jun-Sep 2026

LMAT NASDAQ

LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.

Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.

Rhea-AI Summary

LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. Kamke Trent G reported acquisition or exercise transactions in this Form 4 filing.

LEMAITRE VASCULAR INC (LMAT) reported that Senior V. P., Operations, Trent G. Kamke received multiple dividend equivalent rights awards on September 3, 2026. The awards, in small fractional amounts tied to prior restricted stock unit and performance share unit grants, are each the economic equivalent of one share of common stock and vest proportionately with the underlying awards. No Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
insider
-
Rhea-AI Summary

LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. Roush John A reported acquisition or exercise transactions in this Form 4 filing.

LEMAITRE VASCULAR INC (LMAT) reported that director John A. Roush received multiple small grants of dividend equivalent rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards from December 2023, December 2024, and December 2025.

Each dividend equivalent right is disclosed as the economic equivalent of one share of common stock and will vest proportionately with the underlying stock unit or performance share awards. No cash price was paid for these derivative awards, and no Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
insider
-
Rhea-AI Summary

LEMAITRE VASCULAR INC (LMAT) director John A. Roush exercised employee stock options on September 1, 2026 to acquire 3,444 shares of common stock at an exercise price of $48.60 per share. Following the transaction, he held 7,386 shares directly and 181 shares indirectly through his wife. No Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
insider
Rhea-AI Summary

LeMaitre Vascular reported higher results for the quarter and six months ended June 30, 2026. Quarterly net sales were $70.4 million, up 10% year over year, with net income of $17.1 million and diluted EPS of $0.74. For the first half, net sales reached $136.9 million, also up 10%, and net income was $32.7 million with diluted EPS of $1.42. Growth was driven by higher selling prices, increased volumes, and stronger graft and shunt sales, while catheters declined.

Profitability improved, with gross margin rising to 72.1% in the quarter and 72.4% year-to-date, helped by pricing, product mix, and lower shipping costs. At June 30, 2026, cash and cash equivalents were $26.6 million and short-term marketable securities $349.6 million, against $172.5 million of 2.50% convertible senior notes due 2030. Operating cash flow for the first half was $31.1 million. The company paid $0.50 per share in cash dividends year-to-date and has a $100 million share repurchase authorization in place with no repurchases yet.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.32%
Tags
quarterly report
-
Rhea-AI Summary

LeMaitre Vascular reported strong preliminary, unaudited Q2 2026 results. Net sales were about $70.4M versus $64.2M a year earlier, with net income of $17.1M and diluted EPS of $0.74 versus $0.60. Gross margin reached 72.1%, up 210 bps, and adjusted EBITDA was $22.8M, up 20%.

Growth was led by Artegraft sales up 34%, record grafts, shunts and patches, and double-digit gains in EMEA and APAC. Organic growth excluding catheters was 12%; catheters declined 11% after prior-year recall overstocking. Cash and short-term marketable securities totaled roughly $376M and stockholders’ equity was $420.3M.

The board declared a $0.25 per-share quarterly dividend payable September 3, 2026 and previously authorized up to $100M of share repurchases through February 2027. Guidance calls for 2026 sales of $274.3M–$278.3M (midpoint $276.3M, about 11% growth) and EPS of $2.84–$2.94 (midpoint $2.89), implying 15% GAAP and 21% adjusted EPS growth versus 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.32%
Tags
current report
-
Rhea-AI Summary

LeMaitre Vascular insider Bridget A. Ross filed to sell common stock under a Form 144. The planned sale covers 4,322 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $449,241.48, expected on July 29, 2026 and listed on NASDAQ.

The filing states that the shares relate to a stock option exercise. It also notes that 22,850,739 shares of the issuer’s common stock are outstanding. Over the prior three months, Ross sold 5,044 shares of common stock for aggregate proceeds of $560,366.40 on May 7, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
other
Rhea-AI Summary

LeMaitre Vascular, Inc. has a significant shareholder group consisting of First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation reporting beneficial ownership of 1,175,902 shares of LeMaitre Vascular common stock, representing 5.15% of the class.

The group reports no sole voting or dispositive power. They report shared voting power over 1,170,364 shares and shared dispositive power over 1,175,902 shares, primarily through unit investment trusts and other investment vehicles. The trusts are sponsored or advised by First Trust entities, while voting is generally carried out by the trustee to mirror other shareholders. Each reporting person disclaims beneficial ownership of the reported shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
ownership
-
Rhea-AI Summary

LeMaitre Vascular director Lawrence J. Jasinski reported grants of dividend equivalent rights on existing equity awards. On 2026-06-04, he acquired several small blocks of dividend equivalent rights linked to previously granted restricted stock unit and performance share unit awards from 2023, 2024, and 2025.

Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the underlying awards. These are compensation-related accruals with no open-market buying or selling and no cash exercise price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
insider
-
Rhea-AI Summary

LeMaitre Vascular director John James O’Connor reported routine compensation-related grants of dividend equivalent rights. On June 4, 2026, he acquired several small awards of dividend equivalent rights tied to existing restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and carries a stated price of $0.00 per right. Following these transactions, O’Connor directly holds 5.0674 dividend equivalent rights in total, which vest proportionately with the underlying stock and performance awards rather than representing open-market purchases or sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
insider
Rhea-AI Summary

Roush John A reported acquisition or exercise transactions in this Form 4 filing.

LeMaitre Vascular director John A. Roush reported routine compensation-related transactions in the form of dividend equivalent rights on June 4, 2026. Five separate grants of dividend equivalent rights were credited in fractional amounts, each tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests in step with the underlying equity awards. These awards involve no cash paid by Roush and do not reflect any open-market purchases or sales of shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
insider

FAQ

How many LEMAITRE VASCULAR (LMAT) SEC filings are available on StockTitan?

StockTitan tracks 120 SEC filings for LEMAITRE VASCULAR (LMAT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for LEMAITRE VASCULAR (LMAT)?

The most recent SEC filing for LEMAITRE VASCULAR (LMAT) was filed on November 5, 2026.